PMC9749889_01
(A, D, G) Enhanced T1-weighted brain magnetic resonance image showing cystic brain metastases in a patient with hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer before treatment with abemaciclib and fulvestrant. (B, E, H) Enhanced T1-weighted magnetic resonance image showing that the cystic brain metastases decreased in size after 3 months of treatment with abemaciclib and fulvestrant. (C, F, I) Enhanced T1-weighted magnetic resonance image showing that the cystic brain metastases remained in partial remission after 9 months of treatment with abemaciclib and fulvestrant.
fonc-12-984454-g001.jpg
PMC9749889_01_fonc-12-984454-g001.jpg
f1
After 3 months, the size of CBM significantly decreased ( Figure 1 ), and extracranial bone metastases were stable.